Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Septerna reported positive Phase 1 data for SEP-631, supporting a Phase 2b trial in chronic spontaneous urticaria in the second half of 2026, and initiated a Phase 1 trial for SEP-479 in hypoparathyroidism. The company posted Q1 revenue of $26.5 million, driven by the Novo Nordisk collaboration, compared to $0.2 million in the prior year.
Key figures
- Revenue
- 26523000
- Drug Name
- SEP-631
- Guidance
- Cash runway expected to support operations at least into 2029
- Revenue Yoy
- 11980%
- Phase Of Trial
- Phase 1 (completed), Phase 2b (initiating H2 2026)
- Net loss
- 8637000
- Ga expenses
- 10288000
- Rd expenses
- 29535000
- Cash position
- 522100000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.